Evogen's protein biomarker-based test is designed to stratify actively seizing patients from those who have not experienced a recent seizure.
The device can process high-volume sputum samples for PCR-based Mycobacterium tuberculosis detection at smear-negative, culture-positive levels.
With several SBIR grants from the NIH, the firm is also using its Liquid Scan platform to identify neonatal trophoblast cells in maternal blood samples.
DiaCarta scientists will partner with the University of Florida Health Cancer Center to analyze blood samples from up to 500 cancer patients undergoing radiotherapy.
The firm said it will use the grant to develop an enhanced test panel that covers 80 percent of the most common food allergens, such as milk, peanut, and shellfish.
The grant will support the development of a point-of-care assay designed to detect parasite components with demonstrated diagnostic potential.
The firm plans to make the molecular testing system accessible to low-income countries, in part by reducing costs using reel-to-reel manufacturing.
The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.
The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.
The NSF and NIH awarded the firm separate grants to develop the system, which can provide results in five minutes from a drop of blood.